Foley Strengthens Denver Office With Addition of Health Care Transactional Group

Foley & Lardner LLP announced today that it has further enhanced its Health Care Practice with the addition of partner Jim Miles and senior counsel Charles Gass in Denver, underscoring the firm’s commitment to expanding capabilities in the Health Care and Life Science Sector and its Colorado presence. The attorneys join Foley from Greenberg Traurig, LLP.

Miles represents health care organizations, health care professionals, and private equity firms with commercial transactions, including mergers and acquisitions, equity and debt financing, joint ventures, and start-ups. He advises a range of health care providers, including ambulatory surgical centers, assisted living facilities, community health centers, home health agencies, hospitals, imaging centers, laboratories, pharmaceutical firms, physician practices, and skilled nursing facilities.

Miles also advocates for health care providers undergoing government investigations by the Office of Inspector General, State Medicaid Fraud Control Units, and other government agencies and advises in business planning and government relations.

“Jim and Charles have strong local and Colorado roots, making them an excellent fit for our office and Health Care Sector,” said Emily Weber, managing partner of the firm’s Denver office. “Their highly regarded transactional experience complements that of our Denver-based litigation, antitrust, securities enforcement, government investigations, venture finance, and corporate lawyers. We are thrilled to welcome them to our growing team.”

Gass is an experienced business attorney who advises private companies, private equity sponsors, and strategic investors in complex transactions, including mergers and acquisitions, leveraged buyouts, recapitalizations, equity and debt financing, and general corporate matters. He also counsels health care clients as they navigate regulatory risks and concerns associated with M&A transactions.

“Building upon Foley’s capabilities in the Health Care and Life Sciences Sector is a strategic priority for the firm, and having attorneys of Jim and Charles’ caliber join us adds to that momentum,” said sector chair Susan Pravda. “This group will further enhance our footprint in Colorado and create new opportunities to support our clients both regionally and nationally.”

“Foley’s robust sector approach and nationally acclaimed health care team provide an excellent platform to continue growing our practices,” said Miles. “We were also drawn to the firm’s vibrant culture and thriving Denver office. We look forward to joining our new colleagues to further Foley’s local presence and esteemed health care team.”

About Foley & Lardner LLP
Foley & Lardner LLP is a preeminent law firm that stands at the nexus of the energy, health care and life sciences, innovative technology, and manufacturing sectors. We look beyond the law to focus on the constantly evolving demands facing our clients and act as trusted business advisors to deliver creative, practical, and effective solutions. Our 1,100 lawyers across 25 offices worldwide partner on the full range of engagements from corporate counsel to IP work and litigation support, providing our clients with a one-team solution to all their needs. For nearly two centuries, Foley has maintained its commitment to the highest level of innovative legal services and to the stewardship of our people, firm, clients, and the communities we serve.




Former FDA Chief Counsel Dan Troy Joins BRG as Managing Director

Former FDA Chief Counsel Dan Troy Joins BRG as Managing Director

Global expert services and consulting firm Berkeley Research Group (BRG) announced today that former Federal Drug Administration (FDA) Chief Counsel Dan Troy has joined the firm’s Washington, D.C. office as a managing director in its Health Analytics practice. His pharmaceutical and regulatory expertise will bolster the practice’s ability to address FDA issues on behalf of its clients.

A globally recognized healthcare lawyer, Troy has practiced at the highest levels of the pharmaceutical sector. He served as chief counsel at the FDA and spent a decade as general counsel and senior vice president of GSK plc. Dan was previously a partner at preeminent law firms Sidley Austin LLP and Wiley Rein LLP, where he advised multinational healthcare companies. At BRG, Troy will work with law firms and pharmaceutical companies to provide expert witness testimony on FDA regulatory and related matters.

At the FDA, Troy was a primary liaison to the White House and the Department of Health and Human Services. He spearheaded initiatives on Hatch-Waxman reform, the First Amendment preemption and Securities and Exchange Commission (SEC)–FDA interactions. During his tenure, he oversaw the agency’s litigation and enforcement efforts and helped shape major regulations and guidance.

“No one knows the FDA better than Dan. In his more than 30-year career, he has helped shape, enforce and litigate pharma regulatory matters for leading healthcare organizations, law firms and the government alike,” said Jerry Lewandowski, a managing director in BRG’s Health Analytics practice. “As an expert witness, he’s demonstrated a sterling track record on behalf of generic and branded companies—in areas such as Orange Book listed patents, allegations of fraud and reverse payment antitrust matters—that showcases the breadth of knowledge he will deliver to clients.”

“Simply put, Dan’s experience is unrivaled,” added Edward Buthusiem, a managing director in BRG’s Health Analytics practice. “His addition reflects our commitment to bringing the industry’s preeminent minds to our clients. With Dan on board, BRG clients will have priceless access to a former FDA senior official with decades of experience in both the public and private sectors.”

As general counsel and senior vice president at GSK for a decade, Troy led a global team of more than 630 professionals, including more than 400 attorneys. While there, he employed practical approaches to creatively resolve major issues and litigation, including several high-profile Department of Justice and Foreign Corrupt Practices Act investigations, as well as numerous product liability matters; manage risks; and advise the board and C-suite on global legal matters.

Troy is a highly sought thought leader who has chaired the U.S. Chamber of Commerce Litigation Center and led influential committees and sections within organizations like PhRMA, the American Bar Association and the American Law Institute. He was named a “Legend in the Law” at the 2013 Burton Awards and selected in the Financial Times’ “Global General Counsel 30” in 2016.

Troy’s diverse background combines technical legal skills honed over 30 years in private and governmental sectors. He has also served as a board member with a background in corporate governance, dispute resolution and regulatory compliance.
Commenting on his appointment, Troy said, “I’m thrilled to join such an elite group of healthcare experts at BRG and look forward to combining my extensive private- and public-sector experience to support the firm’s clients in today’s increasingly complex regulatory landscape.”

About BRG
Berkeley Research Group, LLC is a global consulting firm that helps leading organizations advance in three key areas: disputes and investigations, corporate finance, and performance improvement and advisory. Headquartered in California with offices around the world, we are an integrated group of experts, industry leaders, academics, data scientists and professionals working across borders and disciplines. We harness our collective expertise to deliver the inspired insights and practical strategies our clients need to stay ahead of what’s next. Visit thinkbrg.com to learn more.
SOURCE Berkeley Research Group, LLC




Appeals court refuses to reinstate federal employee vaccine mandate while it reviews case

“A federal appeals court said Wednesday it would not reinstate President Joe Biden‘s Covid-19 vaccine mandate for federal employees while it reviews a lower court’s order putting the requirement on hold — potentially setting the stage for the case to go to the Supreme Court,” reports Tierney Sneed in JD Supra.

“The 5th US Circuit Court of Appeals did not explain its reasoning in the unsigned order that said the court was expediting its review of the case. The court said the Biden administration’s request to put the lower court’s ruling on hold was being “carried with the case,” signaling that the appeals court would not rule on the request until it had conducted a fuller review of the case.”

Read the article.

 




Why Many Employers Are Outsourcing COVID-19 Compliance

“Although there are no federally mandated vaccine-or-testing regulations for employees in any industry other than health care, employers still need to comply with state and local rules aimed at protecting their workers from COVID-19. But rather than tracking vaccination status, tests and other precautions internally, many employers are choosing to outsource those efforts to vendors that have emerged to take the onus off of HR,” reports Kylie Ora Lobell in SHRM.

“For example, Ampirical, a 301-employee construction engineering firm in Covington, La., has enlisted the support of Safe Site Check In to manage all COVID-19 procedures, including contact tracing for employees who test positive. Upon arrival at Ampirical’s office, employees and visitors scan a QR code with their smartphone or tablet, then answer six questions and agree to adhere to COVID-19 protocols while they’re onsite, including all construction sites, said the company’s health, safety and environmental manager Rod Courtney.”

Read the article.

 




Pfizer pushes to intervene in lawsuit seeking COVID vaccine information from FDA

“Pfizer Inc wants to intervene in a Texas federal lawsuit seeking information from the U.S. Food and Drug Administration used in licensing the company’s COVID-19 vaccine, a litigation move that plaintiffs who are suing for the data say is premature,” reports Mike Scarcella in Reuters.

“Pfizer’s lawyers at DLA Piper told U.S. District Judge Mark Pittman on Jan. 21 it wanted a role in the proceedings to help the FDA avoid “inappropriately” disclosing trade secret and confidential commercial information.”

Read the article.

 




New York state mask mandate back in effect as judge grants stay in appeal

“An appeals court judge on Tuesday granted a stay in an appeal over mask mandates in New York, keeping the rule in effect during the legal process, New York Attorney General Letitia James said,” reports in Reuters.

“A day earlier, a judge had struck down the state’s mask mandate, one week before it was due to expire. The state attorney general had filed a motion to stay the ruling in an attempt to put it on hold while the state filed a formal appeal.”

Read the article.

 




The “Legal Epidemiology” of Pandemic Control

“The centrality of law as a public health intervention has been undeniable during the Covid-19 pandemic. In just the first half of 2020, more than 1000 laws and orders were issued by federal, state, and local authorities in the United States in an effort to reduce disease transmission,” discuss Scott Burris, J.D., Evan D. Anderson, J.D., Ph.D., and Alexander C. Wagenaar, M.S.W., Ph.D. in The New England Journal of Medicine’s Perspective.

“Legal interventions include stay-at-home orders, mask mandates, and travel restrictions, as well as more particular rules for business operations, alcohol sales, curfews, and health care. Given their heavy use, importance, and obvious socioeconomic side effects, and the social and behavioral complexities of their implementation, one might have expected the National Institutes of Health (NIH), other research funders, and the research community to jump to the work of determining the right mix, intensity, and enforcement approaches of legal restrictions to control transmission with the least and most equitably distributed harms.”

Read the article.




Takeda’s Baxalta Settles with Bayer Over $173M Hemophilia Patent Infringement Verdict

“Takeda subsidiary Baxalta has spent more than two years pushing back against the $173 million in damages it was ordered to pay as a result of Bayer’s hemophilia patent infringement lawsuit. But after an appeals win for Bayer in March, the companies are putting the case to rest,” reports Noah Higgins-Dunn in Fierce Pharma’s Pharma.

“The two drugmakers, along with Nektar Therapeutics, have entered into a settlement agreement over the patent infringement case, a court filing shows. Bayer will not seek claims for the many millions in damages it was owed under a 2019 verdict and a subsequent appeals ruling.”

“Under the latest settlement, each drugmaker will cover their own legal expenses and Baxalta will give up its right to appeal the 2019 verdict any further. The filings didn’t provide other details on the terms of the settlement.”

Read the article.




Navigating the ADA Interactive Process and COVID-19 Disability Accommodation Requests

“As vaccine proliferation continues, employers are preparing to welcome their workforces back to offices and job sites across the country,” write Katharine O. Beattie Sara J. Higgins in Foley & Lardner’s Insights.

“While many Americans are eager to return to pre-pandemic life, employers can expect resistance from employees recalled to the office, particularly from those whose medical conditions put them at greater risk for complications from COVID-19. Reviewing best practices under the Americans with Disabilities Act (ADA) and guidance from the Equal Employment Opportunity Commission, this post provides employers with tips for engaging in an effective interactive process with employees seeking disability accommodations for risks associated with COVID-19.”

Read the blog.




3 Biglaw Firms Will Give Back $1M in Purdue Pharma Legal Fees in Settlement With Trustee

“Three large law firms have agreed to reduce fee applications by $1 million in their bankruptcy representation of Purdue Pharma, the maker of the prescription pain medication OxyContin, after the U.S. trustee alleged a failure to disclose a common interest agreement,” reports Debra Cassens Weiss in ABA Journal’s Verdicts & Settlements.

“The three law firms are Skadden, Arps, Slate, Meagher & Flom; Wilmer Cutler Pickering Hale and Dorr; and Dechert.”

Read the article.




NIST Seeks Comments on Version 2.0 of HIPAA Security Rule Compliance Guidance

“Cyber threats and cybersecurity controls have evolved significantly over the past two decades since the HIPAA Security Rule were originally promulgated. During this same time, healthcare entities have increasingly become a prime target of hackers seeking to extort payment using ransomware, exfiltrate patient data to commit fraud, or disrupt operations in other nefarious ways,” write Alaap B. Shah and Patricia M. Wagner in The National Law Review.

“Recognizing these challenges, some security professionals have sought further clarity on the HIPAA Security Rule that they deem to be ‘long in the tooth’. Yet, regulators have not made any significant modifications – perhaps driven by the original policy considerations of the HIPAA Security Rule that: ‘the standard should be comprehensive and coordinated to address all aspects of security’; that it be “scalable, so that it can be effectively implemented by covered entities of all types and sizes’; and that it ‘not be linked to specific technologies, allowing covered entities to make use of future technology advancements.’

Read the article.




Health Republic Insurance Lawsuit Reaches $220.8M Settlement

“Area health care providers will finally see millions of dollars in reimbursements tied to a defunct health insurer – but some may be out more than half of the dollars they were owed,” reports Tracey Drury in Business Journal’s Health Care.

“The State Department of Financial Services this week announced a $220.8 million judgment resolving a lawsuit filed in late 2017 against the federal government tied to the collapse of Health Republic Insurance of New York.”

“According to DFS, area hospitals and physicians are expected to recoup the full value of unpaid claims. Here’s what wasn’t in the press release: Providers around the state who didn’t know the settlement was in the works signed offers from Riverdale Capital, a New York-based investment firm for pre-payments of 40 cents on the dollar and are now bound by that agreement.”

Read the article.




Businesses Filing More COVID Lawsuits and the Stakes are Higher

“The anniversary of COVID-19 shutdown orders brought an upturn in both the number of business-interruption lawsuits against insurers and the amount of damages they are claiming,” writes Jim Sams in Claims Journal.

“In the past month:

  • A New Jersey hospital system, RWJBarnabas Health, sued Zurich American Insurance Co. seeking $2.5 billion in damages from a virus that sickened 1,000 patients and killed nine staff members.
  • Caesers Entertainment filed suit against 60 carriers seeking $2 billion in damages caused by restrictions at its Las Vegas resort casino. The company said it paid $25 million in premiums for $3.4 billion in coverage through a variety of “all-risk” policies, most of which did not include virus exclusions.
  • Denison University, Kenyon College, Ohio Wesleyan University and the College of Wooster filed suit against their 16 insurers seeking $1.2 billion in coverage. The consortium of private colleges say their insurers turned their backs on them after the virus made their facilities unsafe and uninhabitable.”

“Also, some of the recent filings were made by groups of businesses against a single or multiple insurers. For example, on March 16, six restaurants and a fitness center in New Jersey filed a class-action suit in Bergen County Superior County against six carriers. On the same day, 26 Ohio dental practices filed suit against Amco Insurance Co. in the U.S. District Court in Toledo.”

Read the article.




COVID-19, Info Blocking Provisions: Time for HIPAA Compliance Checkup

“The information blocking provisions of the 21st Century Cures Act officially went into effect this week, putting into focus the Department of Health and Human Services’ regulatory and compliance effort around HIPAA-required data sharing between applicable healthcare entities,” writes Jessica Davis in Health IT Security.

“Enacted by the 21st Century Cures Act in 2017 and implemented by a final rule in 2020, Congress defined information blocking and established penalties for providers that engage in practices that interfere with the access, exchange, and use of electronic health information.”

“The long-awaited info blocking provision established rules and penalties for non-compliance. The law carves out exclusions for providers if they meet an exception established by the HHS Secretary, or for other applicable reasons.”

“Starting April 5, relevant covered entities and business associates must comply. The Office for the National Coordinator recently released insights on just what the law’s enactment means for those relevant providers, as well as the areas HHS will focus on in the next 18 months.”

Read the article.




Purdue Moves to Unload Opioid Claims Via $10B Plan

“Purdue Pharma LP has floated a settlement plan calling for members of the billionaire Sackler family to pay more than $4.2 billion to help resolve the thousands of lawsuits that drove the maker of OxyContin opioid painkillers into bankruptcy,” report Jeremy Hill and Jef Feeley in Bloomberg Law’s Bankruptcy Law.

“Court papers filed late Monday by Purdue call for the drugmaker to hand over the company’s assets to trusts for the benefit of states, cities and counties suing to recoup billions spent dealing with the U.S. opioid crisis. Combined with the cash payment by the Sacklers — the company’s current owners — the Chapter 11 reorganization plan may be worth more than $10 billion, according to court filings.”

“In exchange for the company and the cash, slated to be paid out over nine years, Purdue and the Sacklers would be legally insulated from existing and future opioid lawsuits. Some states, cities and counties that sued the drugmaker oppose the proposal, arguing it doesn’t do enough to hold Purdue’s owners accountable.”

Read the article.




Novartis Unveils Legal Leadership Change as Biotech Hiring Booms

“Novartis AG announced Friday that its global head of litigation, Thomas Kendris, will on an interim basis succeed its outgoing chief legal officer Shannon Thyme Klinger,” reports Brian Baxter in Bloomberg Law’s Business and Practice.

“Novartis said in a statement that Klinger will depart the Swiss drug giant March 15 to return to the U.S. and take a job at ‘a biotechnology company.’ Novartis didn’t identify the company and declined to discuss Klinger’s new role. Klinger didn’t respond to a request for comment on the matter.”

“Her move is the latest in a series of comings-and-goings by law department leaders working for biotechnology startups, drug developers, and medical equipment manufacturers. The health care, life sciences, and pharmaceutical sectors have been busy hiring lawyers within the past year, in part due to the increased demands on some companies stemming from the coronavirus pandemic.”

Read the announcement.




COVID Audits and Investigations: The Enforcers

“As of February 2021, pursuant to the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), which created the Paycheck Protection Program (“PPP”) and supplemental funding such as the Families First Coronavirus Response Act, the United States government has made available an estimated four trillion dollars in relief funds to businesses and individuals, and the Biden administration is proposing roughly two trillion dollars more,” write Merle M. DeLancey Jr. and Craig Stetson in Blank Rome’s Government Contracts Navigator.

“In addition to the relief funds, the Government has easily awarded more than billions in pandemic-related contracts for everything from vaccines to PPE to hand sanitizers. These levels of funding and spending are unprecedented and have been made at breakneck speed (for the government). Based on these factors and lessons from the past, audits of relief recipients and contractors to confirm appropriate use of government funds are inevitable. And the government has said as much. Of course, if an audit reveals potential wrongdoing or malfeasance, relief recipients and contractors should expect follow-on investigations and enforcement activity.”

Read the post.




Humana Agrees to a $12.5M Settlement to Resolve Allegations of Anti-Kickback Violations

“The first of its kind FCA case involves Roche and Medicare Advantage insurer Humana,” report Mary Inman, Esq. and Max Voldman, Esq. in RACmonitor.

“The recent settlement of a whistleblower case involving the government’s Medicare Advantage program might be a sign of things to come for litigation filed under the False Claims Act (FCA), including those initiated by whistleblowers. On Monday, it was announced that the pharmaceutical company Roche and Medicare Advantage insurer Humana have agreed to pay $12.5 million to the U.S. government to resolve allegations that the companies violated the anti-kickback statute. This is the first FCA settlement resulting from a pharmaceutical company’s alleged payment of kickbacks to a Medicare Advantage Organization.”

“Medicare Advantage, also known as Part C of the Medicare program, is a managed care model wherein the government pays Medicare Advantage Organizations (private insurance companies such as Humana) premiums to insure Medicare beneficiaries. The premium amounts are determined by the demographic makeup and the health status of the insured beneficiaries, with sicker, older members drawing a higher payment from the government than younger, healthier ones. This model contrasts with “traditional” Medicare (Parts A and B of the program), wherein the government pays for each individual healthcare service performed, in what is known as a fee-for-service model. In the Medicare Advantage program, the amounts of government payments are not directly linked to which healthcare services are performed.”

Read the article.




Renown Health Pays OCR $75K for HIPAA Right of Access Failure

“The Office for Civil Rights reached a $75,000 civil monetary penalty and corrective action plan with Nevada-based Renown Health, to settle a potential violation of the HIPAA right of access standard,” writes Jessica Davis in Health IT Security’s News.

“The settlement is the fifteenth enforcement discretion brought under the OCR HIPAA Right of Access Initiative since its launch in 2019. The effort is designed to support patients in obtaining timely access to their medical records for a reasonable cost.”

“OCR launched an investigation into Renown Health in February 2019, after receiving a patient complaint that alleged the provider failed to timely respond to their request for an electronic copy of their protected health information. The patient had requested their records, including billing information, to be sent to a third-party.”

Read the article.




Humana and Roche Settle False Claims Act Lawsuit for $12.5M

“Sanford Heisler Sharp, LLP announced that Indianapolis-based Roche Diagnostics Corp. and Roche Diabetes Care, Inc. (‘Roche’) and Louisville-based Humana, Inc., Humana Pharmacy, Inc., and Humana Pharmacy Solutions, Inc. (‘Humana’) have agreed to settle a False Claims Act lawsuit brought by a whistleblower relator (‘Relator’) on behalf of the United States. Defendants will pay $12.5 million to settle the government’s claims, and the Relator will receive a 29% share of the settlement, totaling $3,625,000,” posts Sanford Heisler Sharp LLP in GlobeNewswire.

“Sanford Heisler Sharp represents the Relator who filed the case in 2014 in the U.S. District Court for the Northern District of Illinois under the whistleblower provisions of the False Claims Act.”

“The Relator, a former employee of Roche Diagnostics, alleged that the Defendants violated the Anti-Kickback Statute and False Claims Act, causing false claims to be submitted to the Medicare Advantage program and defrauding taxpayers. Medicare Advantage health plans (sometimes called Medicare Part C) are Government-funded health plans that are administered by private companies known as Medicare Advantage Organizations.”

Read the article.